Cerus Co. (NASDAQ:CERS) Shares Sold by Hsbc Holdings PLC

Hsbc Holdings PLC trimmed its holdings in shares of Cerus Co. (NASDAQ:CERS) by 12.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 118,158 shares of the biotechnology company’s stock after selling 17,410 shares during the quarter. Hsbc Holdings PLC owned approximately 0.06% of Cerus worth $203,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CERS. Hood River Capital Management LLC acquired a new position in Cerus during the first quarter worth $566,000. Wasatch Advisors LP lifted its stake in Cerus by 11.2% in the 4th quarter. Wasatch Advisors LP now owns 6,530,019 shares of the biotechnology company’s stock valued at $14,105,000 after buying an additional 656,971 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Cerus by 2.4% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 7,750,700 shares of the biotechnology company’s stock worth $14,649,000 after buying an additional 182,629 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Cerus by 4.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company’s stock worth $365,000 after buying an additional 8,982 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Cerus by 451.1% during the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 12,179 shares during the last quarter. Hedge funds and other institutional investors own 78.37% of the company’s stock.

Insider Activity at Cerus

In related news, insider Richard J. Benjamin sold 21,605 shares of the firm’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the completion of the sale, the insider now directly owns 438,007 shares of the company’s stock, valued at approximately $1,095,017.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the sale, the chief financial officer now directly owns 590,365 shares in the company, valued at $1,286,995.70. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Richard J. Benjamin sold 21,605 shares of the stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $2.50, for a total transaction of $54,012.50. Following the sale, the insider now directly owns 438,007 shares in the company, valued at $1,095,017.50. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.

Cerus Stock Performance

NASDAQ CERS opened at $1.70 on Friday. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.51 and a quick ratio of 1.83. The stock’s 50 day simple moving average is $2.07 and its 200-day simple moving average is $1.93. The company has a market cap of $314.31 million, a PE ratio of -10.00 and a beta of 1.18. Cerus Co. has a 1-year low of $1.21 and a 1-year high of $2.59.

Cerus (NASDAQ:CERS) last posted its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. The business had revenue of $45.08 million during the quarter, compared to analyst estimates of $42.50 million. Cerus had a negative return on equity of 44.27% and a negative net margin of 14.15%. During the same period in the prior year, the business earned ($0.07) earnings per share. As a group, equities research analysts anticipate that Cerus Co. will post -0.13 EPS for the current fiscal year.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.